Edwards Lifesciences (NYSE:EW) Price Target Increased to $88.00 by Analysts at Piper Sandler

Edwards Lifesciences (NYSE:EW) had its target price raised by Piper Sandler from $85.00 to $88.00 in a research report report published on Friday morning, Benzinga reports. Piper Sandler currently has a neutral rating on the medical research company’s stock.

A number of other brokerages have also recently commented on EW. Morgan Stanley increased their price target on Edwards Lifesciences from $95.00 to $103.00 and gave the company an overweight rating in a research note on Thursday, March 21st. Citigroup raised their target price on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a neutral rating in a research report on Wednesday, April 3rd. StockNews.com lowered Edwards Lifesciences from a buy rating to a hold rating in a research report on Wednesday, March 20th. Bank of America raised Edwards Lifesciences from a neutral rating to a buy rating in a research report on Thursday, March 7th. Finally, Royal Bank of Canada lifted their price objective on Edwards Lifesciences from $95.00 to $101.00 and gave the stock an outperform rating in a research report on Monday, April 15th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of Moderate Buy and an average price target of $93.33.

Edwards Lifesciences Trading Down 1.8 %

Shares of EW stock opened at $86.43 on Friday. The stock’s fifty day moving average price is $90.28 and its two-hundred day moving average price is $78.85. The company has a market cap of $52.02 billion, a PE ratio of 37.25, a P/E/G ratio of 4.36 and a beta of 1.05. Edwards Lifesciences has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 23.34% and a net margin of 23.01%. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Equities analysts predict that Edwards Lifesciences will post 2.76 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $86.67, for a total value of $2,543,764.50. Following the sale, the director now owns 4,486 shares of the company’s stock, valued at approximately $388,801.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock worth $17,166,254 in the last 90 days. Insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

A number of hedge funds have recently modified their holdings of the stock. Martin Capital Advisors LLP raised its holdings in Edwards Lifesciences by 0.5% during the 4th quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock valued at $1,944,000 after acquiring an additional 128 shares during the period. Legacy Wealth Asset Management LLC raised its holdings in Edwards Lifesciences by 0.8% during the 4th quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock valued at $1,293,000 after acquiring an additional 134 shares during the period. Chapin Davis Inc. raised its holdings in Edwards Lifesciences by 1.7% during the 1st quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock valued at $817,000 after acquiring an additional 140 shares during the period. Johnson Financial Group Inc. grew its position in shares of Edwards Lifesciences by 23.0% during the 4th quarter. Johnson Financial Group Inc. now owns 771 shares of the medical research company’s stock valued at $59,000 after purchasing an additional 144 shares in the last quarter. Finally, Valley National Advisers Inc. grew its position in shares of Edwards Lifesciences by 6.0% during the 1st quarter. Valley National Advisers Inc. now owns 2,677 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 152 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.